SynCore Biotechnology to present EndoTAG™ technology platform and its breakthrough product EndoTAG™-1 and novel anti-cancer drug candidate SB01 at Biotech Showcase™ 2016

General Manager, Prof. Muh-Hwan Su, PhD, will present at the Biotech Showcase™ Annual Conference, to be held in San Francisco on January 11-13, 2016.

08 Jan, 2016, 11:40 ET from SynCore Biotechnology

TAIWAN, Jan. 8, 2016 /PRNewswire/ -- SynCore Biotechnology 4F, No.69, DongXing Rd., XinYi Dist., Taipei City 110, Taiwan

A new drug platform and product development biotechnology company in developing the new drug platform for potential cancer treatment and managing the oncology products at clinical stage.
www.syncorebio.com

EndoTAG™ technology platform is a novel, cationic liposomal technology that targets vascular endothelial cells in regenerated blood vessels which carry negative electric charges within the tumor.

SB01 is an injectable formulation of a novel heterocyclic combretastatin A-4 (CA-4) analogue drug candidate that inhibits tubulin polymerization through binding to the colchicine-binding site of tubulin.

EndoTAG™ technology platform is a novel, cationic liposomal technology that targets vascular endothelial cells in regenerated blood vessels which carry negative electric charges within the tumor. Different from the other liposomal-embedded drug delivery systems which directly only targets the cancer cells, EndoTAGdestroys cancerous cells through anti-angiogenesis.

EndoTAG™-1, is a synergistic product of an innovative composition of the established cytotoxic drug paclitaxel combined with EndoTAG™ technology, interacts with newly formed, negatively charged endothelial cells, which are specifically required for the growth of tumor blood vessels. It attacks the activated endothelial cells as they divide, thus EndoTAG™-1 only targets the blood supply to tumors but does not affecting healthy tissues. EndoTAG™-1 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth.

SB01 is an injectable formulation of a novel heterocyclic combretastatin A-4 (CA-4) analogue drug candidate that inhibits tubulin polymerization through binding to the colchicine-binding site of tubulin. It mostly exhibits both tubulin binding ability and cytotoxicity. The action of tubulin binding molecules induces cell cycle arrest in the G2-M phase, forming abnormal mitotic spindles and finally leading to apoptotic cell death. SB01 has initiated Phase II clinical trial in Head and Neck Squamous Cell Carcinoma (HNSCC).

SOURCE SynCore Biotechnology



RELATED LINKS

http://www.syncorebio.com